212Pb-based alpha radioligand therapy (ARTBIO)

N/A

Report date: 2025/11/28 17:54:28

First In Class

Base Information

Drug Name212Pb-based alpha radioligand therapy (ARTBIO)

Drug Alias NameN/A

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lead > 212PbRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionIonising radiation emitters

TargetsUpdating

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator Companies3B Pharmaceuticals GmbH

China Registration ClassN/A

Develop Information

Active CompaniesARTBIO Inc 3B Pharmaceuticals GmbH

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A